Diabetes medications with cardiovascular protection in the wake of EMPA-REG OUTCOME: The optimal combination may be metformin, pioglitazone and empagliflozin

Robert E.J. Ryder, Ralph A. Defronzo

Research output: Contribution to journalEditorialpeer-review

6 Scopus citations
Original languageEnglish (US)
Pages (from-to)151-154
Number of pages4
JournalBritish Journal of Diabetes and Vascular Disease
Issue number4
StatePublished - 2015

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cite this